We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Conjugated linoleic acid suppresses the secretion of atherogenic lipoproteins from human HepG2 liver cells.
- Authors
Ho, S. S. L.; Pal, S.
- Abstract
Background - Studies in healthy humans have shown that consumption of conjugated linoleic acid (CLA) significantly reduced VLDL and LDL cholesterol concentrations in circulation. We propose that the mechanism for decreased lipoprotein levels is due to the inhibition of production and secretion of VLDL (measured by secretion apolipoprotein B100 (apoB100)) from the liver Objective - To investigate the effects of a mixture of CLA isomers on VLDL production and secretion in HepG2 liver cells. Design - HepG2 cells were incubated for 24 h with 50 µM of the different fatty acids or 50 µM of CLA and 50 µM of a saturated fatty acid (SFA). Effects of CLA were compared to that of a SFA (palmitic acid, PA; C16:0), an n-6 polyunsaturated fatty acid (PUFA) (linoleic acid, LA; C18:2) and a blend of CLA and PA (CLA+PA). ApoB100 levels in HepG2 cells were measured using western blotting. Analysis was carried out using student's t-test and ANOVA. Outcomes - ApoB100 secretion was significantly decreased in cells treated with CLA and CLA+PA (44%, p<0.005 and 62%, p<0.0005 respectively) compared to control cells and those enriched with PA. ApoB100 secretion did not differ between CLA and CLA+PA treatments. Conclusions- Collectively, these results show that CLA reduces apoB100 production and secretion compared to SFAs and plant-derived PUFAs, possibly by limiting the availability of free cholesterol (a requirement for apoB100 production), thus extending available evidence suggesting that CLA is potentially anti-atherosclerotic. Another novel finding of this study was that apoB100 secretion was significantly reduced with CLA even in the presence of PA, despite PA being a strong promoter of apoB100 secretion. A reduction of apoB100 production in the body would decrease the number of VLDL and the number of atherogenic LDL and thus reduce the risk of developing cardiovascular disease.
- Publication
Asia Pacific Journal of Clinical Nutrition, 2004, Vol 13, pS70
- ISSN
0964-7058
- Publication type
Academic Journal